WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into an partnership with PsyBrain, Inc. to discover new drugs for treating psychiatric illnesses. According to National Institute for Mental Health approximately one in four adult Americans suffers from a diagnosable mental disorder in a given year, yet there are very few innovative medicines in development. PsyBrain is an emerging start-up company, arising out of a 2012 collaboration between X-Chem and a group of academic, Central Nervous System (CNS), drug development leaders. PsyBrain’s founders include Jerrold Rosenbaum, M.D., Chief of Psychiatry, Massachusetts General Hospital (MGH) and Stanley Cobb Professor of Psychiatry and Maurizio Fava, Executive Vice Chair, MGH Psychiatry and Slater Family Professor of Psychiatry, both from Harvard Medical School.
Help employers find you! Check out all the jobs and post your resume.
